Other Information .
−Removed: During the quarter ended June 30, 2023, none of our officers or directors adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was
−Removed: intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any “non-Rule 10b5-1 trading arrangement”, as defined in Item 408 of Regulation S-K.
Incorporated By
−Removed: Purchase Agreement, dated as of April 5, 2023, by and between Eterna Therapeutics Inc.
−Removed: and Lincoln Park Capital Fund, LLC
−Removed: Exhibit 10.1 to Form 8-K filed on April 11, 2023
−Removed: Registration Rights Agreement, dated as of April 5, 2023, by and between Eterna Therapeutics Inc.
−Removed: and Lincoln Park Capital Fund, LLC
−Removed: Exhibit 10.2 to Form 8-K filed on April 11, 2023
−Removed: Asset Purchase Agreement, dated April 26, 2023, by and among Eterna Therapeutics Inc., Exacis Biotherapeutics Inc., the stockholders party thereto and, with respect to certain provisions, Factor Bioscience
−Removed: Exhibit 10.1 to Form 8-K filed on May 2, 2023
−Removed: Separation Agreement and General Release, dated May 2, 2023, by and between Eterna Therapeutics Inc.
−Removed: and Andrew Jackson.
−Removed: Exhibit 10.1 to Form 8-K filed on May 5, 2023
+Added: Securities Purchase Agreement, dated as of July 13, 2023, by and among Eterna Therapeutics Inc.
+Added: and the purchasers party thereto.
+Added: Exhibit 10.1 to Form 8-K filed on July 18, 2023
+Added: Registration Rights Agreement, dated as of July 13, 2023, by and among Eterna Therapeutics Inc.
+Added: and the purchasers party thereto.
+Added: Exhibit 10.4 to Form 8-K filed on July 18, 2023
+Added: Form of Senior Convertible Note.
+Added: Exhibit 10.2 to Form 8-K filed on July 18, 2023
+Added: Form of Common Stock Purchase Warrant.
+Added: Exhibit 10.3 to Form 8-K filed on July 18, 2023
+Added: First Amendment to Exclusive License Agreement, dated as of July 12, 2023, by and between Eterna Therapeutics Inc.
+Added: and Factor Bioscience Limited.
+Added: Exhibit 10.1 to Form 8-K filed on July 13, 2023
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
19 unchanged sentences
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).
−Removed: Indicates management contract or compensatory plan.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ETERNA THERAPEUTICS INC.
−Removed: August 11, 2023
+Added: November 13, 2023
/s/ Matthew Angel
1 unchanged sentence
Chief Executive Officer and President
−Removed: (on behalf of the Registrant and as Principal Executive Officer)
+Added: (Principal Executive Officer)
+Added: November 13, 2023
+Added: /s/ Sandra Gurrola
+Added: Sandra Gurrola
+Added: Vice President of Finance
+Added: (Principal Financial Officer and Principal Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.